Capecitabine Drug Asset Due Diligence Report 2026

This Capecitabine Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

2541

Registered trials

1885

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Capecitabine can convert its Small molecule drug profile and TYMS biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Capecitabine (query alias: capecitabine)
Modality / target	Small molecule drug; TYMS; TYMS inhibitors
Highest global status	Approved
Originator	F. Hoffmann-La Roche Ltd.
Active developers	Novartis Pharmaceuticals Canada, Inc., UNICANCER, Pfizer Inc.

The MCP disease footprint includes Rectal Cancer, Esophageal Carcinoma, Locally advanced breast cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07700979	Phase 3	Not yet recruiting	900	Overall survival (OS)
NCT07692152	Phase 3	Recruiting	350	Clinical Complete Response (cCR) Rate
NCT07691632	Phase 2	Not yet recruiting	35	Pathological Complete Response Rate

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E-MUTANT COLORECTAL CANCER

Phase 3; n=841; evaluation: not stated. Reported fields: -; SLI: Number of Participants With Dose Limiting Toxicity (DLTs) = 0 Participants ; -

A phase II trial evaluating liposomal irinotecan combined with capecitabine as second-line therapy for biliary tract cancer.

Phase 2; n=20; evaluation: Positive. Reported fields: mPFS = 5.5 month ( 4.50 - NA)

First-line treatment of QLS31905 plus chemotherapy in patients with pancreatic cancer and gastric cancer: Data from a phase 1b/2 study.

Phase 1/2; n=131; evaluation: Positive. Reported fields: ORR = 74.4 % ( 58.83 - 86.48); ORR = 59.8 % ( 48.34 - 70.44)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Capecitabine addresses Rectal Cancer, Esophageal Carcinoma, Locally advanced breast cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2022-04-01	Cheplapharm Arzneimittel GmbH signed an agreement with F. Hoffmann-La Roche Ltd. to acquire the worldwide rights to Xeloda® (capecitabine).	Approved	Financial terms not disclosed
2021-03-29	百洋医药第三方商业化平台又添新伙伴，签入罗氏制药两大经典肿瘤药	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO